(Q34594043)

3 August 2017

A Bayesian population PK-PD model of ispinesib-induced myelosuppression (English)

1 reference

3 August 2017

Kathman SJ

1

1 reference

3 August 2017

Williams DH

series ordinal

2

1 reference

3 August 2017

Hodge JP

series ordinal

3

1 reference

3 August 2017

Dar M

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Clinical Pharmacology & Therapeutics

3 August 2017

1 reference

3 August 2017

81

1 reference

3 August 2017

1

1 reference

3 August 2017

88-94

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100021

3 August 2017

0 references

cites work

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100021

7 January 2021

Mechanistic models for myelosuppression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100021

7 January 2021

Analysis of population pharmacokinetic data using NONMEM and WinBUGS.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100021

7 January 2021

Bayesian measures of model complexity and fit

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100021

7 January 2021

Bayesian analysis of population PK/PD models: general concepts and software

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100021

7 January 2021

Pharmacokinetic/pharmacodynamic modelling in oncological drug development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100021

7 January 2021

A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100021

7 January 2021

Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100021

7 January 2021

Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100021

7 January 2021

Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100021

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100021

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference